AI-Designed Universal Vaccine Enters Human Trials with Early Safety Signals

Researchers at the University of Cambridge used AI to identify stable features across the sarbecovirus family and developed a DNA vaccine intended as a broad-spectrum, potentially universal shot. In the first human trial, the vaccine was safe and elicited antibodies recognizing diverse sarbecoviruses, and its needle-free delivery and stability could aid distribution. However, immune responses were modest, and duration of protection, optimal dosing, and real-world efficacy require larger trials; the goal of a universal vaccine remains years away.